Relay Therapeutics Stock Analysis

Relay Stock Analysis Notes

About 98.0% of the company shares are owned by institutional investors. The book value of Relay Therapeutics was at this time reported as 3.52. The company has Price/Earnings To Growth (PEG) ratio of 0.07. Relay Therapeutics recorded a loss per share of 1.72. The entity had not issued any dividends in recent years. Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Relay Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 320 people. To find out more about Relay Therapeutics contact MA MBA at 617 370 8837 or learn more at https://www.relaytx.com.

Relay Therapeutics Investment Alerts

Relay Largest EPS Surprises

View All Earnings Estimates

Relay Therapeutics Environmental, Social, and Governance (ESG) Scores

Relay Stock Institutional Investors

Note, although Relay Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Relay Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.56 B.

Relay Profitablity

Management Efficiency

Relay Therapeutics has return on total asset (ROA) of (0.2537) % which means that it has lost $0.2537 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4115) %, meaning that it created substantial loss on money invested by shareholders. Relay Therapeutics' management efficiency ratios could be used to measure how well Relay Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.47 in 2026. Return On Capital Employed is likely to drop to -0.55 in 2026. At this time, Relay Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 33.7 M in 2026, whereas Total Assets are likely to drop slightly above 855.6 M in 2026.

Technical Drivers

As of the 12th of February 2026, Relay Therapeutics holds the Semi Deviation of 3.38, risk adjusted performance of 0.114, and Coefficient Of Variation of 749.88. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Relay Therapeutics, as well as the relationship between them.

Relay Therapeutics Price Movement Analysis

Relay Therapeutics Insider Trading Activities

Relay Therapeutics Outstanding Bonds

Relay Therapeutics Predictive Daily Indicators

Relay Therapeutics Corporate Filings

Relay Therapeutics Forecast Models

Relay Therapeutics' time-series forecasting models are one of many Relay Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Relay Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Relay Therapeutics Bond Ratings

Relay Therapeutics financial ratings play a critical role in determining how much Relay Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Relay Therapeutics' borrowing costs.

Relay Therapeutics Debt to Cash Allocation

Relay Therapeutics currently holds 48.5 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Relay Therapeutics has a current ratio of 14.92, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Relay Therapeutics' use of debt, we should always consider it together with its cash and equity.

Relay Therapeutics Total Assets Over Time

Relay Therapeutics Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Relay Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Relay Therapeutics Debt Ratio

3.3

It appears most of the Relay Therapeutics' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Relay Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Relay Therapeutics, which in turn will lower the firm's financial flexibility.

Relay Therapeutics Corporate Bonds Issued

Relay Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Relay Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Relay shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Relay Therapeutics. By using and applying Relay Stock analysis, traders can create a robust methodology for identifying Relay entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Relay analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Relay analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Relay Therapeutics stock analysis indicators help investors evaluate how Relay Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Relay Therapeutics shares will generate the highest return on investment. By understating and applying Relay Therapeutics stock analysis, traders can identify Relay Therapeutics position entry and exit signals to maximize returns.

When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.